Trial
NCT02576119
A Study to Determine the Effect of Multiple Doses of BMS-955176 on the Electrocardiograph of Healthy Subjects
Phase ITERMINATEDSAFETYConfidence: HIGH
Sponsor
ViiV Healthcare
Collaborators
GlaxoSmithKline
Condition
Infection, Human Immunodeficiency Virus
Intervention
BMS-955176, Placebo (Part 1)
Why stopped
This study was terminated early due to neuropsychiatric serious adverse events reported by 2 participants.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-08-09